出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/05/15 10:45:47」(JST)
| Osteosarcoma | |
|---|---|
|
Intermediate-magnification micrograph of an osteosarcoma (center and right of image) adjacent to non-malignant bone (left-bottom of image): The top-right of the image has poorly differentiated tumor. Osteoid with a high density of malignant cells is seen between the non-malignant bone and poorly differentiated tumor (H&E stain).
|
|
| Classification and external resources | |
| Specialty | Oncology |
| ICD-10 | C40-C41 |
| ICD-9 | 170 |
| ICD-O | M9180/3 |
| OMIM | 259500 |
| DiseasesDB | 9392 |
| MedlinePlus | 001650 |
| eMedicine | ped/1684 orthoped/531 radio/504 radio/505 |
| MeSH | D012516 |
Osteosarcoma is a cancerous tumor in a bone. Specifically, it is an aggressive malignant neoplasm that arises from primitive transformed cells of mesenchymal origin (and thus a sarcoma) and that exhibits osteoblastic differentiation and produces malignant osteoid.[1]
Osteosarcoma is the most common histological form of primary bone cancer.[2] It is most prevalent in children and young adults.[3]
Many patients first complain of pain that may be worse at night, and may have been occurring for some time. Also, teenagers who are active in sports tend to complain about pain in their lower femur, or right below the knee. If the tumor is large, it can appear as a swelling. Sometimes a sudden fracture of bone is the first symptom because affected bone is not as strong as normal bones and may fracture with minor trauma (a pathological fracture). According to Bone Cancer Research Trust, the pain may come and go and vary in intensity. The swelling will not be visible if it is not near the surface of the body such as on the pelvis.
Several research groups are investigating cancer stem cells and their potential to cause tumors.[4] Radiotherapy for unrelated conditions may be a rare cause.[5]
Despite persistent rumors suggesting otherwise, there is no clear association between water fluoridation and cancer or deaths due to cancer, both for cancer in general and also specifically for bone cancer and osteosarcoma.[6] Series of research concluded that concentration of fluoride in water doesn't associate with osteosarcoma. The beliefs regarding association of fluoride exposure and osteosarcoma stem from a study of US National Toxicology program in 1990, which showed uncertain evidence of association of fluoride and osteosarcoma in male rats. But there is still no solid evidence of cancer-causing tendency of fluoride in mice.[7] Fluoridation of water has been practiced around the world to improve citizens' dental health. It is also deemed as major health success.[8] Fluoride concentration levels in water supplies are regulated, such as United States Environmental Protection Agency regulates fluoride levels to not be greater than 4 milligrams per liter.[9] Actually, water supplies already have natural occurring fluoride, but many communities chose to add more fluoride to the point that it can reduce tooth decay.[10] Fluoride is also known for its ability to cause new bone formation.[11] Yet, further researches shows no osteosarcoma risks from fluoridated water in humans.[12] Most of the researches involved counting number of osteosarcoma patients cases in particular areas which has difference concentrations of fluoride in drinking water.[13] The statistic analysis of the data shows no significant difference in occurrences of osteosarcoma cases in different fluoridated regions.[14] Another important research involved collecting bone samples from osteosarcoma patients to measure fluoride concentration and compare them to bone samples of newly diagnosed malignant bone tumors. The result is that the median fluoride concentrations in bone samples of osteosarcoma patients and tumor controls are not significantly different.[15] Not only fluoride concentration in bones, Fluoride exposures of osteosarcoma patients are also proven to be not significantly different from healthy people. [16]
Osteosarcomas tend to occur at the sites of bone growth, presumably because proliferation makes osteoblastic cells in this region prone to acquire mutations that could lead to transformation of cells (the RB gene and p53 gene are commonly involved). Due to this tendency, high incidence of osteosarcoma is seen in some large dog breeds (St. Bernards and Great Danes). The tumor may be localized at the end of the long bone (commonly in the metaphysis). Most often it affects the proximal end of tibia or humerus, or distal end of femur. Osteosarcoma tends to affect regions around the knee in 60% of cases, 15% around the hip, 10% at the shoulder, and 8% in the jaw. The tumor is solid, hard, irregular ("fir-tree," "moth-eaten", or "sun-burst" appearance on X-ray examination) due to the tumor spicules of calcified bone radiating in right angles. These right angles form what is known as Codman's triangle, which is characteristic but not diagnostic of osteosarcoma. Surrounding tissues are infiltrated.
Microscopically: The characteristic feature of osteosarcoma is presence of osteoid (bone formation) within the tumor. Tumor cells are very pleomorphic (anaplastic), some are giant, numerous atypical mitoses. These cells produce osteoid describing irregular trabeculae (amorphous, eosinophilic/pink) with or without central calcification (hematoxylinophilic/blue, granular) - tumor bone. Tumor cells are included in the osteoid matrix. Depending on the features of the tumor cells present (whether they resemble bone cells, cartilage cells, or fibroblast cells), the tumor can be subclassified. Osteosarcomas may exhibit multinucleated osteoclast-like giant cells.[17]
Family physicians and orthopedists rarely see a malignant bone tumor (most bone tumors are benign). The route to osteosarcoma diagnosis usually begins with an X-ray, continues with a combination of scans (CT scan, PET scan, bone scan, MRI) and ends with a surgical biopsy. A characteristic often seen in an X-ray is Codman's triangle, which is basically a subperiosteal lesion formed when the periosteum is raised due to the tumor. Films are suggestive, but bone biopsy is the only definitive method to determine whether a tumor is malignant or benign.
The biopsy of suspected osteosarcoma should be performed by a qualified orthopedic oncologist. The American Cancer Society states: "Probably in no other cancer is it as important to perform this procedure properly. An improperly performed biopsy may make it difficult to save the affected limb from amputation." It may also metastasise to the lungs, mainly appearing on the chest X-ray as solitary or multiple round nodules most common at the lower regions.
[18]
A complete radical, surgical, en bloc resection of the cancer, is the treatment of choice in osteosarcoma.[2] Although about 90% of patients are able to have limb-salvage surgery, complications, particularly infection, prosthetic loosening and non-union, or local tumor recurrence may cause the need for further surgery or amputation.
Mifamurtide is used after a patient has had surgery to remove the tumor and together with chemotherapy to kill remaining cancer cells to reduce the risk of cancer recurrence. Also, the option to have rotationplasty after the tumor is taken out exists.[19]
Patients with osteosarcoma are best managed by a medical oncologist and an orthopedic oncologist experienced in managing sarcomas. Current standard treatment is to use neoadjuvant chemotherapy (chemotherapy given before surgery) followed by surgical resection. The percentage of tumor cell necrosis (cell death) seen in the tumor after surgery gives an idea of the prognosis and also lets the oncologist know if the chemotherapy regimen should be altered after surgery.
Standard therapy is a combination of limb-salvage orthopedic surgery when possible (or amputation in some cases) and a combination of high-dose methotrexate with leucovorin rescue, intra-arterial cisplatin, adriamycin, ifosfamide with mesna, BCD (bleomycin, cyclophosphamide, dactinomycin), etoposide, and muramyl tripeptide. Rotationplasty may be used. Ifosfamide can be used as an adjuvant treatment if the necrosis rate is low.
Despite the success of chemotherapy for osteosarcoma, it has one of the lowest survival rates for pediatric cancer. The best reported 10-year survival rate is 92%; the protocol used is an aggressive intra-arterial regimen that individualizes therapy based on arteriographic response.[20] Three-year event-free survival ranges from 50% to 75%, and five-year survival ranges from 60% to 85+% in some studies. Overall, 65-70% patients treated five years ago will be alive today.[21] These survival rates are overall averages and vary greatly depending on the individual necrosis rate.
Fluids are given for hydration, while antiemetic drugs (such as the 5-HT3 receptor antagonists e.g. granisetron and ondansetron) help with nausea and vomiting. Filgrastim or pegfilgrastim help with white blood cell counts and neutrophil counts. Blood transfusions and epoetin alfa help with anemia.
Osteosarcoma is the eighth-most common form of childhood cancer, comprising 2.4% of all malignancies in pediatric patients, and about 20% of all primary bone cancers.[2]
Incidence rates for osteosarcoma in U.S. patients under 20 years of age are estimated at 5.0 per million per year in the general population, with a slight variation between individuals of black, Hispanic, and white ethnicities (6.8, 6.5, and 4.6 per million per year, respectively). It is slightly more common in males (5.4 per million per year) than in females (4.0 per million per year).[2]
It originates more frequently in the metaphyseal region of tubular long bones, with 42% occurring in the femur, 19% in the tibia, and 10% in the humerus. About 8% of all cases occur in the skull and jaw, and another 8% in the pelvis.[2]
Around 300 of the 900 people diagnosed in the United States will die each year. A second peak in incidence occurs in the elderly, usually associated with an underlying bone pathology such as Paget's disease of bone.
Prognosis is separated into three groups.
Deaths due to malignant neoplasms of the bones and joints account for an unknown number of childhood cancer deaths. Mortality rates due to osteosarcoma have been declining at about 1.3% per year. Long-term survival probabilities for osteosarcoma have improved dramatically during the late 20th century and approximated 68% in 2009.[2]
In the UK and Ireland, the Bone Cancer Research Trust funds research and provides information on osteosarcoma and other bone cancers, including information for teenagers who have this condition. In the US, the nonprofit organization Triumph Over Kid Cancer Foundation helps not only to raise awareness about osteosarcoma, but also helps raise funds to try to improve treatment and survivability of pediatric bone cancer. About 90% of their proceeds go to research and M.D. Anderson Cancer Hospital matches those funds dollar for dollar, and use all funds for research in pediatric sarcoma. The work will be done under the auspices of the Children's Sarcoma Initiative, and will feature a committee to solicit new research ideas in this area and fund those most likely to lead to progress. Also, because early diagnosis greatly improves prognosis, they work on educational efforts to increase awareness of bone cancer's signs and symptoms in parents and their pediatricians. Finally, since the life of pediatric bone cancer patients is so difficult, TOKC sets aside 10% of its proceeds to help fund the Sunshine Kids Organization, which works to bring some brief periods of happiness to the lives of these children.
Osteosarcoma is the most common bone tumor in dogs and typically afflicts middle-aged large and giant breed dogs such as Irish Wolfhounds, Greyhounds, German Shepherds, Rottweilers, mountain breeds (Great Pyrenees, St. Bernard, Leonberger, Newfoundland), Doberman Pinschers and Great Danes. It has a 10-fold greater incidence in dogs than humans.[24] A hereditary base has been shown in St. Bernard dogs.[25] Spayed/neutered dogs have twice the risk of intact ones to develop osteosarcoma.[26] Infestation with the parasite Spirocerca lupi can cause osteosarcoma of the esophagus.[27]
The most commonly affected bones are the proximal humerus, the distal radius, the distal femur, and the tibia,[28] following the basic premise "far from the elbow, close to the knee". Other sites include the ribs, the mandible, the spine, and the pelvis. Rarely, osteosarcoma may arise from soft tissues (extraskeletal osteosarcoma). Metastasis of tumors involving the limb bones is very common, usually to the lungs. The tumor causes a great deal of pain, and can even lead to fracture of the affected bone. As with human osteosarcoma, bone biopsy is the definitive method to reach a final diagnosis. Osteosarcoma should be differentiated from other bone tumours and a range of other lesions, such as osteomyelitis. Differential diagnosis of the osteosarcoma of the skull in particular includes, among others, chondrosarcoma and the multilobular tumour of bone.[29][30]
Amputation is the initial treatment, although this alone will not prevent metastasis. Chemotherapy combined with amputation improves the survival time, but most dogs still die within a year.[28] Surgical techniques designed to save the leg (limb-sparing procedures) do not improve the prognosis.
Some current studies indicate osteoclast inhibitors such as alendronate and pamidronate may have beneficial effects on the quality of life by reducing osteolysis, thus reducing the degree of pain, as well as the risk of pathological fractures.[31]
Osteosarcoma is also the most common bone tumor in cats, although not as frequently encountered, and most typically affects the rear legs. The cancer is generally less aggressive in cats than in dogs, so amputation alone can lead to a significant survival time in many affected cats, though post-amputation chemotherapy is recommended when a high grade is confirmed on histopathology.[28]
|author-separator= (help)|author-separator= (help)|author-separator= (help)|author-separator= (help)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
| リンク元 | 「骨肉腫」「OS」 |
| 拡張検索 | 「osteosarcomatous」 |
| 骨肉腫 | ユーイング肉腫 | |
| 概念 | 類骨を形成する悪性骨腫瘍 骨組織に原発し、腫瘍細胞が直接類骨あるいは骨組織を形成する。 |
分化の高悪性度小円形細胞肉腫。発生母細胞は神経外胚葉 |
| 疫学 | 15歳ピーク 10歳代:60% 20歳代:15% 男性にやや多い |
10-30歳で見られるが、10代から10代未満に好発し、80%が20歳以下である。骨肉腫より若年者に好発する。 男女比 = 2:1 |
| 原発性悪性骨腫様のなかで最多 | 骨肉腫、骨髄腫、軟骨肉腫に次いで多い。 | |
| 好発部位 |
大腿骨遠位 脛骨近位 合わせて75% 次いで上腕骨近位 |
長幹骨の骨幹部 骨盤、大腿骨、上腕骨、脛骨の順に好発する |
| 症状 | 腫脹、疼痛、腫瘍の増大で発赤、局所熱感、静脈怒張 | 疼痛、腫脹、全身症状(白血球増多、発熱) |
| 血液検査 | 血清アルカリフォスファターゼ、乳酸脱水素酵素 | 白血球増多、CRP上昇、赤沈亢進 |
| 単純X線写真 | 骨硬化を伴わない骨破壊、種々の程度の腫瘍性骨新生(境界不明瞭の淡い綿花様、綿球様の骨硬化) 外骨膜反応(コットマン三角、スピクラ形成) |
骨皮質を破壊しつくす前にフォルクマン管を介して軟部組織に浸潤し骨外に浸潤する。このために骨膜を持ち上げ骨膜反応(たまねぎの皮様(onion skin appearance))を呈する。 斑点状、蚕喰状の骨吸収破壊像 |
| 転移 | 血行性、肺転移 | |
| 予後 | 5年生存率50-70% | 予後不良 日本での5年累積生存率は45% |